The increase in price target from $111 to $123 suggests that JP Morgan sees potential upside in Cardinal Health's stock, which could lead to a positive short-term impact on the stock price. However, the Neutral rating indicates a balanced view, suggesting that while there is potential for growth, there are also factors that may limit the stock's performance.